Company Overview of Altimmune, Inc.
Altimmune, Inc. operates as a clinical stage immunotherapeutic biotechnology company that develops immunotherapeutic products and vaccines to address public health and biodefense needs. It offers NasoVAX, an intranasally administered recombinant influenza vaccine; HepTcell, an immunotherapy for the chronic hepatitis B virus infection; NasoShield, which provides protection after a single intranasal administration; and Oncosyn, an immunotherapeutic in preclinical testing for the treatment of solid cancers. The company also develops products for use in companion and commercial livestock, including cats, dogs, horses, swine, poultry, and aquaculture. It offers immunotherapeutic products for vari...
19 Firstfield Road
Gaithersburg, MD 20878
Founded in 1997
Key Executives for Altimmune, Inc.
Chief Executive Officer, President and Director
Outside General Counsel and Secretary
Compensation as of Fiscal Year 2015.
Altimmune, Inc. Key Developments
Altimmune, Inc. Presents at Ladenburg Thalmann 2015 Healthcare Conference, Sep-29-2015 11:30 AM
Sep 4 15
Altimmune, Inc. Presents at Ladenburg Thalmann 2015 Healthcare Conference, Sep-29-2015 11:30 AM. Venue: Sofitel Hotel, New York, New York, United States.
Vaxin Inc. Appoints Elizabeth Adkins Czerepak as Chief Financial Officer
Apr 13 15
Vaxin Inc. strengthened its leadership team by appointing Elizabeth Adkins Czerepak to the newly created position of chief financial officer (CFO). Ms. Czerepak is a finance expert with over 20 years of executive experience in the pharmaceutical, biotech, and venture capital industries. As Vaxin's CFO, she will grow the company's finance organization, oversee M&A activities, and drive interactions with the investor community. A seasoned finance executive, Ms. Czerepak has led a broad range of initiatives at public and privately held companies. As a venture capital investor and board member at Bear Stearns Health Innoventures (BSHI), she played a key role in raising hundreds of millions of dollars in private financings and IPOs, and achieving $537 million and $364 million acquisitions of portfolio companies.
Vaxin Inc. Presents at BioCentury 22nd Annual Future Leaders in the Biotech Industry Conference, Mar-20-2015 01:50 PM
Mar 17 15
Vaxin Inc. Presents at BioCentury 22nd Annual Future Leaders in the Biotech Industry Conference, Mar-20-2015 01:50 PM. Venue: Millennium Broadway Hotel & Conference Center, New York, New York, United States. Speakers: William Enright, Chief Executive Officer, President and Director.
Similar Private Companies By Industry
Recent Private Companies Transactions